UY29903A1 - Dialurea para el tratamiento de la hipertension pulmonar - Google Patents

Dialurea para el tratamiento de la hipertension pulmonar

Info

Publication number
UY29903A1
UY29903A1 UY29903A UY29903A UY29903A1 UY 29903 A1 UY29903 A1 UY 29903A1 UY 29903 A UY29903 A UY 29903A UY 29903 A UY29903 A UY 29903A UY 29903 A1 UY29903 A1 UY 29903A1
Authority
UY
Uruguay
Prior art keywords
treatment
pulmonary hypertension
dialurea
fluorophenosi
trifluoromethylphenyl
Prior art date
Application number
UY29903A
Other languages
English (en)
Spanish (es)
Inventor
Dr Martina Klein
Dr Joachim Hutter
Dr Peter Sandner
Dr Hanna Tinel
Dr Bernd Riedl
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY29903A1 publication Critical patent/UY29903A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY29903A 2005-11-10 2006-11-07 Dialurea para el tratamiento de la hipertension pulmonar UY29903A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
UY29903A1 true UY29903A1 (es) 2007-06-29

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29903A UY29903A1 (es) 2005-11-10 2006-11-07 Dialurea para el tratamiento de la hipertension pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (enExample)
EP (1) EP1948170A1 (enExample)
JP (1) JP5084736B2 (enExample)
KR (1) KR20080067000A (enExample)
AR (1) AR057849A1 (enExample)
AU (1) AU2006312714A1 (enExample)
BR (1) BRPI0618522A2 (enExample)
CA (1) CA2628849A1 (enExample)
CR (1) CR9953A (enExample)
EC (1) ECSP088430A (enExample)
GT (1) GT200800058A (enExample)
IL (1) IL191178A0 (enExample)
NO (1) NO20082498L (enExample)
PE (1) PE20070806A1 (enExample)
SV (1) SV2009002900A (enExample)
TW (1) TW200733961A (enExample)
UY (1) UY29903A1 (enExample)
WO (1) WO2007054216A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) * 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
AU2004212633B2 (en) * 2003-02-21 2010-12-09 ResMed Pty Ltd Nasal assembly
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
WO2006034797A1 (en) * 2004-09-29 2006-04-06 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008089389A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
WO2009156070A1 (en) * 2008-06-25 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
WO2011130728A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
EP2621486A1 (en) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324825A1 (en) * 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
ES2303585T3 (es) * 2002-04-10 2008-08-16 Virginia Commonwealth University Combinacion de glivec(sti571) con un inhibidor de quinasa dependiente de ciclina, especialmente flavopiridol en el tratamiento de cancer.
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) * 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Also Published As

Publication number Publication date
AR057849A1 (es) 2007-12-19
WO2007054216A1 (en) 2007-05-18
CR9953A (es) 2008-10-08
SV2009002900A (es) 2009-04-28
AU2006312714A1 (en) 2007-05-18
IL191178A0 (en) 2009-08-03
EP1948170A1 (en) 2008-07-30
JP2009514910A (ja) 2009-04-09
PE20070806A1 (es) 2007-09-29
GT200800058A (es) 2010-02-23
ECSP088430A (es) 2008-07-30
BRPI0618522A2 (pt) 2011-09-06
CA2628849A1 (en) 2007-05-18
JP5084736B2 (ja) 2012-11-28
KR20080067000A (ko) 2008-07-17
US20100035888A1 (en) 2010-02-11
TW200733961A (en) 2007-09-16
NO20082498L (no) 2008-08-07

Similar Documents

Publication Publication Date Title
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
PT1485080E (pt) Utilização de adapaleno para o tratamento de desordens dermatológicas
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
NO20090623L (no) Forbindelser for behandling av proliferative lidelser
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
TN2010000074A1 (en) Cyclic depsipeptides
CL2007003189A1 (es) Compuestos derivados de indol y benzofurano; composicion farmaceutica; y uso para el tratamiento o la prevencion de la enfermedad de alzheimer.
NO20076405L (no) Anvendelse av 24-nor-UDCA
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
MX2010001243A (es) Composicion anti-inflamatoria.
WO2003105751A3 (en) Novel curcumin derivatives
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
CL2008000949A1 (es) Compuestos derivados de 2,3-benzodiazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos psicoticos.
ATE437988T1 (de) Neues imprägnierverfahren einer textiloberfläche

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160920